Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time
{{output}}
With the advent of survival motor neuron (SMN)-enhancing therapies, the natural course of spinal muscular atrophy (SMA) has been reshaped, unveiling new patient phenotypes. As therapeutic options expand, there is an increasing demand for robust biomarkers to e... ...
